Leadership at Sutura

Meet our Leadership Team of highly experienced industry experts, dedicated to the development of innovative therapeutics.

James Noble, Chairman

James Noble, Chairman

James Noble joined Sutura Therapeutics as Chairman in February 2020. He has held numerous senior executive positions and brings over 35 years of experience in the international biotechnology industry and investment banking. He has previous served as Finance Director for British Biotechnology Group, raising over $300 million and taking the company public in London and on NASDAQ. Subsequently, he has been a founder and CEO of Avidex Limited, raising $60 million; he also co-founded Immunocore Limited, which has raised in excess of $400 million and Adaptimmune Therapeutics PLC, raising over $650 million via partnering, private placings, a NASDAQ listing and subsequent secondary offerings. He is a non-executive board member at Adaptimmune Therapeutics and Deputy Chairman of GW Pharmaceuticals (both NASDAQ-listed) and on the board of private company Celleron Therapeutics; he previously has held non-executive directorships at more than dozen biotechnology companies.

Mark Beards, Chief Executive Officer

Mark Beards, Chief Executive Officer

Mark Beards is the CEO of the company. He was formally the Chief Executive Officer at UTILITY therapeutics, which is focused on developing and commercialising antibiotics in the US, to address the significant threat faced by healthcare systems and patients from multi-drug resistant bacterial infections.

Mark has over 28 years’ experience in the life sciences and financial sectors within both global organisations and early stage companies. He has previously held the role of Corporate Development Director, then Group Chief Financial Officer and Executive Board Member, of Celixir plc, a clinical stage biotechnology company focused on developing cellular regenerative therapies.

He brings a detailed understanding of the life sciences industry from his time at Abbott Laboratories (sales & marketing) and GlaxoSmithKline (R&D) This is augmented by his time at McKinsey & Company as a management consultant focused on supporting senior pharmaceutical clients. He has held a number of senior roles in organisations such as Goldman Sachs (Vice President and Head of European Healthcare Equity Research), Charles River Associates (VP, Life Science Strategy), and KPMG (Director, Life Science Strategy)

Mark holds a BA (Hons) and MA in Mathematics from The Queen’s College, Oxford University, and is a fully qualified Chartered Management Accountant

Eduardo Bravo,  Non-Executive Director

Eduardo Bravo, Non-Executive Director

Eduardo Bravo has more than 25 years’ experience in the biopharmaceutical industry and a strong track record in leading and growing international biotech and pharmaceutical organizations. From 2011-2018 Eduardo was the CEO of TiGenix, a dual-listed (Euronext, Brussels and NASDAQ) biopharmaceutical company developing novel stem cell therapies. He successfully developed TiGenix through several financing rounds, led its IPO on NASDAQ and secured European marketing approval of its lead asset. In January 2018, Takeda Pharmaceutical Co. Ltd announced it was acquiring TiGenix. Prior to joining TiGenix predecessor, Cellerix, in 2005, Eduardo held several senior management positions at Sanofi-Aventis and SmithKline Beecham. He has been CEO of Nordic Nanovector, a public Norwegian company from July 2018 to February 2020, successfully completing two oversubscribed financing rounds with European and US investors. He is currently Chairman of Vivet Therapeutics, a private gene therapy company.
Eduardo holds a degree in Business Administration and an MBA from INSEAD.

Keith Foster, Chief Scientific Officer

Keith Foster, Chief Scientific Officer

Dr. Keith Foster is a translational biologist with over 20 years’ experience in developing gene, cell and pharmaceutical medicines for Duchenne muscular dystrophy (DMD) and metabolic diseases. He is currently an Associate Professor in Translational Medicine at the University of Reading and runs a state of the art research laboratory at the University of Reading that is able to facilitate medicine development and subsequent analyses in pre-clinical disease models. Keith is the inventor of a technology to enhance the in vivo delivery of antisense oligonucleotides to target tissues such as muscle, heart and brain.

Keith is part of a number of networks of excellence; acts on the scientific editorial board of numerous scientific journals; acts as an expert reviewer for grant applications and supports a number of scientific advisory boards for medical research charites.

Keep Informed

Sign up for future updates

Thank you